Jorge Duconge to Aryl Hydrocarbon Hydroxylases
This is a "connection" page, showing publications Jorge Duconge has written about Aryl Hydrocarbon Hydroxylases.
Connection Strength
3.229
-
Reyes-Gonz?lez S, de Las Barreras C, Reynaldo G, Rodr?guez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 08 18; 35(4).
Score: 0.748
-
Duconge J, Cadilla CL, Seip RL, Rua?o G. Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J. 2015 Sep; 34(3):175-7.
Score: 0.530
-
Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, Alejandro-Cowan Y, Kocherla M, Cruz I, Feliu JF, Cadilla CL, Renta JY, Gorowski K, Vergara C, Rua?o G, Duconge J. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics. 2012 Dec; 13(16):1937-50.
Score: 0.438
-
Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Rua?o G, Duconge J. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother. 2012 Feb; 46(2):208-18.
Score: 0.413
-
Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Rua?o G. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis. 2009; 19(4):390-5.
Score: 0.334
-
Duconge J, Cadilla CL, Renta JY, Sil?n-Rivera P, Piovanetti P, Garc?a-Berdec?a R, Castro-Rosario LM, Monz?n S, V?lez L, Rosas G, Guerra JA, Santiago-Borrero PJ. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. P R Health Sci J. 2008 Dec; 27(4):357-8.
Score: 0.332
-
Rodr?guez-Fern?ndez K, Reynaldo-Fern?ndez G, Reyes-Gonz?lez S, de Las Barreras C, Rodr?guez-Vera L, Vlaar C, Monbaliu JM, Stelzer T, Duconge J, Mangas-Sanjuan V. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model. Biomed Pharmacother. 2024 Jan; 170:115977.
Score: 0.235
-
Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Rua?o G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 06; 411(17-18):1306-11.
Score: 0.092
-
Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Rua?o G. For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription. Ethn Dis. 2009; 19(4):479-80.
Score: 0.084
-
Seip RL, Duconge J, Rua?o G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010 May; 6(3):409-24.
Score: 0.023